In addition to the four abstracts, three moderated ePosters will be shared on the disease progression of ATTR- CM in a real-world setting, a retrospective cohort study on manifestation to diagnosis of ATTR-CM, and data on the cause of death of ATTR-CM patients in the ATTRibute-CM study. Rapid-fire Abstract Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM Presenter: Anique Ducharme, M.D., Université de Montréal, CAN Dat ...

Core Insights - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on genetic diseases, participating in the Bank of America Merrill Lynch Global Healthcare Conference 2025 [1][3] - The company aims to discover, create, test, and deliver transformative medicines for patients with genetic diseases, with a pipeline that includes early science to advanced clinical trials [3] Company Overview - Founded in 2015, BridgeBio is committed to applying advances in genetic medicine to expedite patient care [3] - The company has a team of experienced professionals in drug discovery and development [3] Event Participation - Management will engage in a fireside chat at the conference on May 14, 2025, at 2:20 pm PT [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $116.6 million, consisting of $36.7 million in attributed net product revenue and $79.9 million in license and services revenue, primarily driven by a regulatory milestone related to BEYONDRA's EU approval [32][33] - The net present value (NPV) increased by 9% due to factors such as faster uptake of Atruvio and a decrease in the model cost of capital [9][10] Business Line Data and Key Metrics Changes - Atruvio generated $36.7 million in revenue in its first full quarter, indicating strong demand across major prescribers and patient segments [5][31] - The company has three additional blockbuster products in the pipeline, with ongoing trials in Limb Girdle Muscular Dystrophy, achondroplasia, and ADH1 [7][16] Market Data and Key Metrics Changes - The market for ATTR Centimeters is estimated to be around $15 billion, with the company targeting a peak year sales goal of $4.3 billion, representing about 30% market share [16][17] - The company reported that 2,072 unique patients received a prescription for Atruvio, with 756 unique healthcare providers writing at least one prescription [23][24] Company Strategy and Development Direction - The company aims to maximize positive change in quality-adjusted life years for patients by developing meaningful medicines quickly, focusing on first-in-class or best-in-class therapies [10][11] - The strategy includes a focus on late-stage genetic disease businesses and maintaining a sustainable competitive advantage through effective commercialization [15][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for Atruvio, driven by its differentiated clinical efficacy and strong patient support programs [41][42] - The company anticipates continued growth in the market for ATTR Centimeters, with a focus on newly diagnosed patients and a commitment to reaching as many patients as possible [91][92] Other Important Information - The company expects modest growth in quarterly operating expenses for the remainder of the year, with cash and cash equivalents at $540.6 million, excluding anticipated regulatory milestone payments [35][36] - The company has received regulatory approval for BEYONDRA in Japan, expecting to recognize a $30 million milestone in Q2 [32] Q&A Session Summary Question: Can you provide granularity on the tailwind driving the quarter's performance? - Management highlighted differentiated clinical efficacy, market growth, and effective access programs as key drivers of demand [41][42] Question: Can you quantify the paid conversion rate and inventory impact? - The conversion rate is tracking well, with limited inventory impact as sales were primarily driven by demand [52][55] Question: What is resonating with healthcare professionals regarding Atruvio? - Positive feedback centers on the drug's rapid efficacy and strong clinical data, leading to repeat prescriptions [78][81] Question: How do you view new patient starts for the category going forward? - Management expects continued high numbers of new diagnoses, driven by increased awareness and education among healthcare providers [90][91] Question: What are the expectations for the Limb Girdle Muscular Dystrophy data? - Management remains optimistic about the potential for approval based on positive clinical outcomes observed in trials [66][73]

Financial Performance - BridgeBio Pharma reported a quarterly loss of $0.88 per share, which was better than the Zacks Consensus Estimate of a loss of $1, representing an earnings surprise of 12% [1] - The company posted revenues of $116.63 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 86.76%, although this is a decline from year-ago revenues of $211.12 million [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Since the beginning of the year, BridgeBio Pharma shares have increased by approximately 30.8%, contrasting with a decline of 6% in the S&P 500 [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.98 on revenues of $60.98 million, and for the current fiscal year, it is -$4.18 on revenues of $255.08 million [7] - The estimate revisions trend for BridgeBio Pharma is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Revenue and Financial Performance - For the three months ended March 31, 2025, total revenues decreased by $94.5 million to $116.6 million compared to the same period in 2024, driven by a $131.2 million decrease in license and services revenue and a $36.7 million increase in net product revenue [301]. - The company generated net product revenue of $36.7 million during the three months ended March 31, 2025, following the FDA approval and commercial launch of Attruby [291]. - The company incurred a net loss of $169.6 million for the three months ended March 31, 2025, compared to a net loss of $36.2 million for the same period in 2024 [292]. - Cash and cash equivalents decreased to $540.6 million as of March 31, 2025, down from $681.1 million as of December 31, 2024 [300]. - Net product revenue for the three months ended March 31, 2025, was $36.7 million from the commercial sale of Attruby in the U.S. [303]. - The company incurred a net loss of $169.6 million for the three months ended March 31, 2025, compared to a net loss of $36.2 million for the same period in 2024 [323]. - The company expects to continue incurring operating and net losses over the next several years as it funds drug development and commercial launch readiness [323]. Expenses - Research and development expenses for the three months ended March 31, 2025, were $111.4 million, compared to $141.0 million for the same period in 2024 [299]. - Selling, general and administrative expenses increased to $106.4 million for the three months ended March 31, 2025, compared to $65.8 million for the same period in 2024 [299]. - Research and development expenses decreased by $29.5 million to $111.431 million for the three months ended March 31, 2025, mainly due to divestment of two early-stage R&D affiliates and a decrease in external costs [308]. - Selling, general and administrative expenses increased by $40.6 million to $106.365 million for the three months ended March 31, 2025, primarily due to increased personnel-related expenses and marketing initiatives [311]. Cash Flow and Financing Activities - For the three months ended March 31, 2025, net cash used in operating activities was $199.2 million, consisting of a net loss of $169.6 million and a net cash outflow of $116.1 million related to changes in operating assets and liabilities [363]. - Net cash provided by financing activities was $60.3 million for the three months ended March 31, 2025, primarily from $575.0 million in proceeds from the issuance of 2031 Notes [368]. - The company completed a public offering of 9,913,793 shares at a price of $29.00 per share, resulting in net proceeds of $276.6 million after fees [333]. - The company received net proceeds of approximately $537.0 million from the 2020 Note Offering after deducting expenses, with $49.3 million used for Capped Call Transactions and $75.0 million for share repurchases [351]. Debt and Obligations - The company fully repaid $467.0 million under the Amended Financing Agreement on February 28, 2025, using proceeds from the issuance of $575.0 million in 2031 Notes [294]. - As of March 31, 2025, the company had cash and cash equivalents of $540.6 million and outstanding debt of $1.8 billion [322]. - The principal balances of the company's 2031 Notes, 2029 Notes, and 2027 Notes were $575.0 million, $747.5 million, and $550.0 million, respectively, with fixed interest rates [374]. - The company issued $575.0 million principal amount of 2031 Notes with a 1.75% interest rate, maturing on March 1, 2031 [336][337]. - The company issued $747.5 million principal amount of 2029 Notes with a 2.25% interest rate, maturing on February 1, 2029 [342][343]. - The company issued $550.0 million principal amount of 2027 Notes with a 2.50% interest rate, maturing on March 15, 2027 [349][350]. Partnerships and Agreements - The company received an upfront payment of $135.0 million under the Bayer License Agreement and is eligible for up to $150.0 million in regulatory and sales milestone payments through 2026 [296]. - The company recognized $75.0 million in license and services revenue related to regulatory milestones achieved under the Bayer License Agreement for the three months ended March 31, 2025 [302]. - The company entered into a partnership with Kyowa Kirin, receiving an upfront payment of $100.0 million and potential royalties up to the mid-twenties percent on sales of infigratinib in Japan [331]. - The company entered into a Funding Agreement with Purchasers for $500.0 million upon FDA approval of acoramidis, with a royalty interest payment of 5% on global net sales, adjustable to a maximum of 10% in 2027 [356][357]. Economic and Operational Outlook - The company is exploring business opportunities to partner, divest, or delay certain R&D programs to drive operational changes and cost savings [327]. - The company is closely monitoring economic conditions and supply chain issues that may negatively impact financial and operating results [329]. - The company expects its cash, cash equivalents, and restricted cash to fund operations for at least the next 12 months based on current operating plans and financial forecasts [328]. - The company has not experienced significant risks due to changes in interest rates, as its fixed-rate debt is not subject to variability [375].

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $116.6 million, consisting of $36.7 million in attributed net product revenue and $79.9 million in license and services revenue [34] - Attributed net product revenue of $36.7 million was driven by strong demand across all major prescribers and patient segments [34] - Total operating expenses for Q1 2025 were $218.4 million, compared to $210.2 million in the same period last year, reflecting continued investment in the Atruvio brand and advancing late-stage pipeline [35] Business Line Data and Key Metrics Changes - The launch of Atruvio generated $36.7 million in revenue, indicating strong clinician and patient resonance with its clinical efficacy and safety [7][34] - The company reported 2,072 unique patients receiving prescriptions for Atruvio through April 25, with 756 unique healthcare providers writing at least one prescription [25] - The company expects to achieve peak year sales of $4.3 billion, representing about 30% of a $15 billion marketplace for Atruvio [18] Market Data and Key Metrics Changes - The market for ATTR Centimeters is estimated to have 250,000 to 300,000 patients in the U.S., with only about 50,000 diagnosed, indicating significant growth potential [44] - The company is seeing early uptake across all major prescriber and patient segments, including large academic centers and community cardiologists [25][26] Company Strategy and Development Direction - The company aims to maximize positive change in quality-adjusted life years for patients by developing meaningful medicines quickly, focusing on high-probability technical success programs [11][16] - BridgeBio is committed to a transparent commercial model that prioritizes patient access and support, differentiating itself from competitors [30] - The company plans to launch three additional commercial products in 2026 and 2027, expanding its portfolio [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for Atruvio, attributing it to differentiated clinical efficacy and strong access programs [44][46] - The company anticipates modest growth in quarterly operating expenses for the remainder of the year, offset by Atruvio sales [35] - Management highlighted the importance of physician education and the growing market for ATTR therapies as key drivers for future growth [44][45] Other Important Information - The company received a $75 million regulatory milestone related to BEYONDRA's EU approval and expects to recognize a $30 million milestone in Q2 for BEYONDRA's approval in Japan [34] - The company ended the quarter with $540.6 million in cash and cash equivalents, excluding anticipated regulatory milestone payments [37] Q&A Session Summary Question: Can you provide granularity on the tailwind and what is working well? - Management noted that the demand is driven by differentiated clinical efficacy, market growth, and effective access programs [44][46] Question: Can you quantify the paid conversion rate and stocking in the quarter? - Management indicated that conversion rates are consistent or better than historical launches, with minor inventory impact on total sales [53][57] Question: What is resonating with healthcare professionals regarding the Atruvio launch? - Positive feedback has been received regarding the drug's rapid efficacy and strong patient support programs [84][86] Question: How do you expect new patient starts to evolve going forward? - Management expects continued growth in new patient diagnoses, driven by increased awareness and education among healthcare professionals [99][100] Question: What are the biggest hurdles for adoption? - The main hurdles include ensuring physicians are aware of the drug's benefits and navigating the competitive landscape as new entrants emerge [84][86]

Financial Performance - Revenues for Q1 2025 were $116.6 million, a decrease of $94.5 million compared to $211.1 million in Q1 2024, primarily due to a $131.2 million drop in license and services revenue[11] - The net loss attributable to common stockholders for Q1 2025 was $167.4 million, compared to a net loss of $35.2 million in Q1 2024, resulting in a net loss per share of $0.88[20] - Total revenues for the three months ended March 31, 2025, were $116.633 million, a decrease from $211.120 million in the same period of 2024, representing a decline of approximately 44.7%[23] - The net loss for the first quarter of 2025 was $169.608 million, compared to a net loss of $36.160 million in the first quarter of 2024, indicating a significant increase in losses[23] - Operating costs for Q1 2025 were $221.0 million, an increase from $210.8 million in the same period last year, driven by a $40.5 million rise in selling, general and administrative expenses[15] - Total other expense for Q1 2025 was $65.2 million, an increase of $28.7 million compared to $36.5 million in Q1 2024, primarily due to higher interest expenses[18] - The total operating costs and expenses for the first quarter of 2025 were $221.005 million, compared to $210.777 million in the same period of 2024, an increase of approximately 4.9%[23] - The company incurred interest expense of $42.141 million in the first quarter of 2025, compared to $23.471 million in the same period of 2024, indicating an increase of approximately 79.3%[23] Cash and Assets - The company ended Q1 2025 with $540.6 million in cash and cash equivalents, down from $681.1 million at the end of 2024, reflecting a net cash used in operating activities of $199.2 million[10] - Cash and cash equivalents as of March 31, 2025, were $540.599 million, down from $681.101 million at the end of 2024, a decrease of approximately 20.7%[26] - The total assets as of March 31, 2025, were $881.638 million, a decrease from $919.338 million at the end of 2024, representing a decline of about 4.1%[26] - The company reported a net cash used in operating activities of $199.235 million for the first quarter of 2025, compared to $219.537 million in the same period of 2024, showing a decrease of approximately 9.2%[29] Clinical Trials and Product Development - The Phase 3 trial for BBP-418 in LGMD2I/R9 is fully enrolled with 112 participants, and the interim analysis topline readout is expected in the second half of 2025[8] - The Phase 3 trial of encaleret for ADH1 is also fully enrolled with 71 participants, with topline results anticipated in the second half of 2025[8] - BridgeBio expects encaleret to potentially become the first approved therapy for the treatment of ADH1[35] - The company anticipates BBP-812 could be the first therapeutic option for children born with Canavan disease[35] - BridgeBio plans to advance encaleret to a chronic hypoparathyroidism registrational study[35] - The expected completion of enrollment for BBP-812 in the CANaspire pivotal Phase 1/2 study is a key milestone[35] - BridgeBio is conducting multiple clinical trials, including the ACT-EARLY Phase 3 study[35] Regulatory and Market Considerations - Acoramidis was approved in the U.S., EU, UK, and Japan, with a significant 59% risk reduction for all-cause mortality or first cardiovascular-related hospitalization reported in a study subgroup[6] - The company expects to receive $105 million in regulatory milestone payments in Q2 for ex-U.S. approvals of BEYONTTRA®[10] - The company acknowledges potential risks related to regulatory approvals and market conditions[35] - BridgeBio's forward-looking statements are subject to risks and uncertainties that could lead to actual results differing materially[35] Strategic Focus and Funding - The company is focused on the commercial success of Attruby/BEYONTTRA[35] - BridgeBio is actively seeking additional funding through less dilutive sources than equity financings[35] - The company is monitoring macroeconomic factors, including inflation and geopolitical events, that may impact operations[35]

Core Insights - BridgeBio Pharma reported $36.7 million in net product revenue for Attruby in its first full quarter, with 2,072 unique patient prescriptions written by 756 prescribers as of April 25, 2025 [1][2] - The company has made significant progress in its clinical trials, including the full enrollment of the observational run-in study for hypochondroplasia Phase 2 trial ahead of schedule [1][6] - BridgeBio ended the quarter with $540.6 million in cash and cash equivalents, excluding anticipated regulatory milestone payments of $105 million for ex-U.S. approvals of BEYONTTRA [1][9] Commercial Progress - The first full quarter of Attruby net product revenue was $36.7 million, with 2,072 unique patient prescriptions written by 756 healthcare providers since FDA approval in November 2024 [2][13] - The Chief Commercial Officer highlighted a 42% reduction in all-cause mortality and a 50% decrease in cardiovascular hospitalizations at 30 months for patients treated with Attruby [3] Pipeline Overview - Acoramidis for ATTR-CM is approved in the U.S., EU, Japan, and UK, with the first participant in the ACT-EARLY Phase 3 trial expected to be dosed in 2025 [4] - BBP-418 for LGMD2I/R9 and encaleret for ADH1 have completed enrollment in their Phase 3 studies, with topline results expected in the second half of 2025 [4][6] - Infigratinib for achondroplasia is fully enrolled, with topline results anticipated in early 2026 [4][6] Key Program Updates - Attruby has shown strong clinical efficacy and safety, contributing to its growth in the ATTR-CM treatment paradigm [5][6] - The Phase 2 proof-of-principle study of encaleret in hypoparathyroidism showed 78% of participants achieving normal calcium levels within 5 days, with plans to advance to a registrational study in 2026 [6][7] Financial Updates - Cash and cash equivalents decreased to $540.6 million as of March 31, 2025, primarily due to operating activities and loan repayments [9][10] - Total revenues for the three months ended March 31, 2025, were $116.6 million, down from $211.1 million in the same period the previous year, mainly due to a decrease in license and services revenue [10][11] - The company recorded a net loss attributable to common stockholders of $167.4 million for the quarter, compared to a loss of $35.2 million for the same period in 2024 [20]

Core Insights - The UK has granted marketing authorization for acoramidis, branded as BEYONTTRA, for treating wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) [1][2] - Acoramidis is the first and only approved treatment for ATTR-CM in the U.S., EU, UK, and Japan, with a label specifying near-complete stabilization (≥90%) of transthyretin (TTR) [1][3] - The approval is based on positive results from the Phase 3 ATTRibute-CM study, which demonstrated significant cardiovascular benefits [2][3] Summary by Category Product Approval - The Medicines and Healthcare products Regulatory Agency in the UK has approved acoramidis for ATTR-CM treatment [1][2] - Acoramidis has previously received approvals in the U.S. as Attruby™ and in the EU and Japan as BEYONTTRA [3] Clinical Study Results - The ATTRibute-CM study involved 632 participants and showed a 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30 compared to placebo [1][2] - A 50% reduction in the cumulative frequency of cardiovascular-related hospitalization events was also observed at Month 30 [1] Market and Financial Aspects - BridgeBio will receive royalties in a tiered structure starting in the low-thirties percent on sales of BEYONTTRA in the UK [1][4][5] - Bayer is responsible for all commercial activities related to acoramidis in the UK [1][3]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating BridgeBio Pharma, Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is on behalf of BridgeBio Pharma's shareholders [1]. - The law firm specializes in representing shareholders affected by securities fraud and breaches of fiduciary duty [3]. - Shareholders seeking more information can contact the firm for free [2].